Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Johnson & Johnson — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.93B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 125.4× VanEck JP Morgan EM Local Currency Bond ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 38 Days and Johnson & Johnson for 129 Days on average.
| EMLC | JNJ | |
|---|---|---|
Market Cap | $4.93B | $618.09B |
Volume | 2,843,860 | 6,050,983 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $278.43 |
52-Week Low | $24.53 | $186.00 |
Typical Hold Time | 38 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.78, showing minimal daily change. The technical outlook is bearish, with moving averages and ADX signaling a downtrend, while oscillators are neutral. Recent news highlights the ETF hitting a 52-week low amid a strengthening U.S. dollar, which pressures emerging market local currency bonds. No fundamental financial ratios are available in the provided data, limiting traditional valuation analysis.
The outlook remains cautious due to macroeconomic headwinds like dollar strength and potential Fed rate hikes. Risks include currency volatility and rising bond yields. Analyst sentiment appears bearish, with the ETF facing challenges in the near term, though diversification benefits in foreign bonds may offer long-term value if conditions stabilize.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
